Unicycive Therapeutics, Inc. (UNCY)

NASDAQ: UNCY · IEX Real-Time Price · USD
0.730
-0.011 (-1.43%)
Aug 12, 2022 3:57 PM EDT - Market closed
-1.43%
Market Cap 10.97M
Revenue (ttm) n/a
Net Income (ttm) -12.59M
Shares Out 15.03M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,324
Open 0.748
Previous Close 0.740
Day's Range 0.701 - 0.748
52-Week Range 0.624 - 3.190
Beta n/a
Analysts Buy
Price Target 9.82 (+1,245.6%)
Earnings Date Aug 15, 2022

About UNCY

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. [Read more...]

Industry Biotechnology
IPO Date Jul 13, 2021
Employees 9
Stock Exchange NASDAQ
Ticker Symbol UNCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for UNCY stock is "Buy." The 12-month stock price forecast is 9.82, which is an increase of 1,245.57% from the latest price.

Price Target
$9.82
(1,245.57% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Unicycive Reports Key Findings from Independent Renal Dietitian Survey

Hyperphosphatemia ranked as area of greatest unmet need

Unicycive Reports Key Findings from Market Research with Nephrologists

Renazorb product profile rated as best-in-class phosphate binder

Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.

NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a n...

Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Unicycive Therapeutics, Inc. (Nasdaq: UNCY) concerning the Company and its directors' and officers' possible...

Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases

Event Features Discussion with Glenn Chertow, M.D., MPH, Professor of Medicine at Stanford University School of Medicine Event Features Discussion with Glenn Chertow, M.D., MPH, Professor of Medicine at...

Unicycive Announces Full Year 2021 Financial Results and Provides Business Update

On track to initiate clinical bioequivalence study of Renazorb to treat hyperphosphatemia in healthy volunteers in first half of 2022

Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022

In Recognition of National Kidney Month In Recognition of National Kidney Month

Unicycive to Present at Upcoming March Investor Conferences

LOS ALTOS, Calif. , March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announc...

Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation S...

LOS ALTOS, Calif., Feb. 2, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced...

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

LOS ALTOS, Calif. , Jan. 10, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announc...

Unicycive Therapeutics Receives FDA Guidance On Renazorb Regulatory Pathway

Unicycive Therapeutics Inc (NASDAQ: UNCY) updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate).  Renazorb is a second-generation lanthanum-based phosphate-bindin...

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided...

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results

LOS ALTOS, Calif., Nov. 11, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported...

Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announce...

Unicycive Therapeutics to be Added to Russell Microcap® Index

LOS ALTOS, Calif., Sept. 15, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announc...

Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announce...

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

LOS ALTOS, Calif., Aug. 16, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported...

Roth Capital Initiates Coverage On Newly Listed Unicycive

Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target.  Analyst Elemer Piros says that the Company could submit a marketing application to the...